SKYE BIOSCIENCE INC
SKYENASDAQTrading Snapshot
- Day Range
- $1.57 – $1.62
- 52-Week Range
- $1.50 – $39.92
- Volume
- $2.02B
- Avg Volume
- $2.55B
- Shares Outstanding
- 4.4M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $285,222
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-10.18
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.8%
Why Investors Own SKYE
- ✓High-growth profile — revenue up +1.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SKYE BIOSCIENCE INC
SKYE
StockOtter · stockotter.spaceAbout SKYE BIOSCIENCE INC
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) major shareholder 5Am Partners Vii, Llc sold 33,892 shares of Skye Bioscience stock in a transaction on Wednesday, September 16th. The shares were sold at an average
Andrew Schwab Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) Director Andrew Schwab sold 33,892 shares of Skye Bioscience stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $1.91, fo
Skye Bioscience to Merge With Redx, Forming Fibrosis-Focused Fibrx Therapeutics
Skye Bioscience (NASDAQ: SKYE) and privately held Redx announced a definitive transaction agreement that would combine the companies into a Nasdaq-listed fibrosis-focused biotechnology company named Fibrx Therapeutics. T
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor f
Skye Bioscience (NASDAQ:SKYE) Trading 2.8% Higher – Time to Buy?
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report)'s share price was up 2.8% during mid-day trading on Monday. The stock traded as high as $0.5918 and last traded at $0.5842. Approximately 102,145 shares were traded